AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33189854
Drug: Gastric Electrical
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric Electrical Stimulation (Enterra therapy)
Trial: 33190629
Drug: ≥50 mL/(kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≥50 mL/(kg · day) human milk
Trial: 33191112
Drug: Relebactam/imipenem/cilastatin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relebactam/imipenem/cilastatin (250 mg/500 mg/500 mg) dosed every 6 h for 5-14 days
Trial: 33191169
Drug: Minimal residual
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal residual disease measurement and preemptive therapies
Trial: 33191774
Drug: F/TDF at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F/TDF at 33% of daily dosing
Trial: 33191774
Drug: F/TDF at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F/TDF at 67% of daily dosing
Trial: 33191774
Drug: F/TDF at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F/TDF at 100% of daily dosing
Trial: 33192400
Drug: Medtronic Activa
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medtronic Activa PC+ S device stimulation in the supplementary motor area (SMA) and ventral capsule/ventral striatum (VC/VS)
Trial: 33192504
Drug: Spironolactone, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone, dosage and duration not specified
Trial: 33192504
Drug: Dry Extract,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry Extract, dosage and duration not specified
Trial: 33192706
Drug: RG7203 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7203 (two doses)
Trial: 33195707
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (n = 147)
Trial: 33195874
Drug: Higher frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher frequency point-of-care (POC) viral load (VL) and targeted drug resistance mutation (DRM) testing
Trial: 33196449
Drug: Self-administered intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intervention with assistance via chat
Trial: 33196449
Drug: Self-administered intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intervention without assistance via chat
Trial: 33196581
Drug: DAPT discontinuation
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT discontinuation <6 months after PCI
Trial: 33196581
Drug: Resuming or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resuming or starting cancer treatment (chemotherapy, radiation therapy, or surgery) after PCI
Trial: 33196581
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of aspirin and early P2Y12 inhibitor discontinuation
Trial: 33198671
Drug: Lenvatinib 24
RxNorm normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 24 mg orally once daily in 28-day cycles
Trial: 33198674
Drug: Neoadjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant systemic chemotherapy, HIPEC and CRS (conversion therapy group)
Trial: 33198674
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and HIPEC (palliative chemotherapy group)
Trial: 33198674
Drug: Neoadjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant systemic chemotherapy and HIPEC
Trial: 33198781
Drug: Lung cancer
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung cancer screening with baseline health questionnaire, spirometry, and low-dose CT scan.
Trial: 33199917
Drug: Drug-target enrichment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-target enrichment analysis
Trial: 33200217
Drug: Sirolimus (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (oral administration, dose-adjusted to maintain a therapeutic range of 6-15 ng/ml for 6 months)
Trial: 33200217
Drug: Sirolimus (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (oral administration)
Trial: 33201358
Drug: Liposomal irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal irinotecan 50 or 70 mg/m²
Trial: 33201789
Drug: Subharmonic-aided pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subharmonic-aided pressure estimation (SHAPE) using a US contrast agent and saline infusion
Trial: 33203317
Drug: Behaviour change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour change intervention to support memory and brain health, details on dosage and duration not available
Trial: 33203645
Drug: Neratinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib at 240 mg/day with cetuximab (standard dosage)
Trial: 33203645
Drug: Neratinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib at lower doses (120 mg, 160 mg, 200 mg) with cetuximab (standard dosage)
Trial: 33203665
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg daily from day 1 plus nivolumab 3 mg/kg intravenously on day 15, then every 2 weeks (phase Ib)
Trial: 33203665
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg for the first 14 days (induction) then 25 mg per day plus nivolumab on the same schedule (phase II)
Trial: 33204764
Drug: Hydroxychloroquine (once-daily)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (once-daily)
Trial: 33204764
Drug: Hydroxychloroquine (twice-weekly)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (twice-weekly)
Trial: 33204764
Drug: Hydroxychloroquine (once-weekly)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (once-weekly)
Trial: 33205032
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with bevacizumab (Group A) for cycles 3-6
Trial: 33205032
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy without bevacizumab (Group B) for cycles 3-6
Trial: 33205280
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication
Trial: 33205510
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment with mechanical debridement plus systemic amoxicillin/metronidazole for 7 days
Trial: 33206198
Drug: Botulinum toxin-A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum toxin-A injection alongside physical therapies
Trial: 33206198
Drug: Botulinum toxin-A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum toxin-A injection
Trial: 33206198
Drug: Therapy following
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy following botulinum toxin-A injection
Trial: 33206198
Drug: Commercially-available botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially-available botulinum toxin-A agents
Trial: 33207247
Drug: GDF-15 neutralization
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDF-15 neutralization with monoclonal antibody mAB1
Trial: 33207247
Drug: Chemotherapy agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy agents with high clinical emetic score
Trial: 33208134
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high physical work demands and high leg pain intensity
Trial: 33208326
Drug: Direct-acting antivirals
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antivirals (DAAs) treatment consisting of sofosbuvir and daclatasvir for 12 weeks, with ribavirin added in cases of cirrhosis.
Trial: 33209056
Drug: Serratus anterior
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serratus anterior plane block (SAPB) with 25 mL bupivacaine 0.25%
Trial: 33209056
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with 25 mL bupivacaine 0.25%
Trial: 33209626
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy combined with immunotherapy (pembrolizumab)
Trial: 33209626
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment strategies
Trial: 33210217
Drug: Family-administered delirium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-administered delirium detection tools
Trial: 33210276
Drug: Liraglutide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.2 mg/day) as add-on therapy to metformin (1500-3000 mg/day) for 4 months
Trial: 33210333
Drug: Vedolizumab Q8W
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab Q8W dosing
Trial: 33211315
Drug: Pimasertib (28-255
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib (28-255 mg/day)
Trial: 33211842
Drug: Loncastuximab tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loncastuximab tesirine (ADCT-402) at doses ranging from 15 to 200 µg/kg, with a recommended dose of 150 µg/kg every 3 weeks for 2 doses followed by 75 µg/kg every 3 weeks.
Trial: 33212251
Drug: Collection tube
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collection tube type (heparin vs Cell Save (CS) preservation tubes)
Trial: 33212251
Drug: Treatment effect
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effect (pre- vs post-chemotherapy)
Trial: 33214209
Drug: Inhaled TD139
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled TD139 (0.3-10 mg, once daily for 14 days)
Trial: 33214209
Drug: Inhaled TD139
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled TD139 (0.15-50 mg, single doses)
Trial: 33214615
Drug: Preemptive interferon-α
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive interferon-α (IFN-α) treatment
Trial: 33214879
Drug: Telemedicine solution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine solution for the post-anesthesia care unit
Trial: 33215602
Drug: Rectal thermometer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal thermometer (REC)
Trial: 33216238
Drug: Sufentanil sublingual
RxNorm normalized name: SUFentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil sublingual tablet system (SSTS) 15 mcg
Trial: 33216238
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone extended release 10 mg twice daily and oral oxycodone immediate-release 5 mg up to four times daily on demand (Oxy group)
Trial: 33216238
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone (Oxy group)
Trial: 33216287
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab (TCZ-SC) treatment
Trial: 33216356
Drug: Nivolumab and
RxNorm normalized name: nivolumab and relatlimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab and ipilimumab (nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg intravenously every 3 weeks for 4 doses, followed by 480 mg of nivolumab intravenously every 4 weeks)
Trial: 33216772
Drug: Serum apolipoprotein-A1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum apolipoprotein-A1 at 1.25 g/L cutoff
Trial: 33217193
Drug: Any treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any treatment for recurrence
Trial: 33217357
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody treatment (mAB114 or REGN-EB3)
Trial: 33218740
Drug: Agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Agalsidase alfa treatment
Trial: 33219014
Drug: Talimogene laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Talimogene laherparepvec (TVEC) at dose level 1 (DL 1 = 10) combined with neoadjuvant chemotherapy (NAC)
Trial: 33219014
Drug: Talimogene laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Talimogene laherparepvec (TVEC) at dose level 2 (DL 2) combined with neoadjuvant chemotherapy (NAC)
Trial: 33221175
Drug: Telisotuzumab vedotin
RxNorm normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telisotuzumab vedotin 2.7 mg/kg administered intravenously every 3 weeks until disease progression or unacceptable toxicity
Trial: 33221715
Drug: Bifrontal transcranial
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifrontal transcranial direct current stimulation (tDCS) applied using a 2 mA current for 20 min, twice daily, for 5 consecutive weekdays.
Trial: 33222307
Drug: Frequent antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent antibiotic use
Trial: 33222307
Drug: Higher nasal
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher nasal expression of IL-17 and T1R3 (sweet taste receptor)
Trial: 33222379
Drug: Carbapenem monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbapenem monotherapy (primarily meropenem)
Trial: 33222379
Drug: BLBLI monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLBLI monotherapy (mostly piperacillin-tazobactam)
Trial: 33222379
Drug: Any active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any active therapy (including BLBLI and carbapenem)
Trial: 33222803
Drug: Oral tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tenofovir disoproxil fumarate and emtricitabine for PrEP, taken daily for the first 12 weeks.
Trial: 33224628
Drug: SAR439459 (pan-TGFβ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR439459 (pan-TGFβ neutralizing antibody)
Trial: 33224628
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SAR439459 with anti-PD-1
Trial: 33224753
Drug: Rivaroxaban (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (once daily)
Trial: 33224753
Drug: Dabigatran (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (twice daily)
Trial: 33224806
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone (treatment group, n=41)
Trial: 33225383
Drug: Impaired Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired Activity of Daily Living scale score
Trial: 33225717
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose intake during an oral glucose tolerance test, assessed by indirect calorimetry for measuring diet-induced thermogenesis (DIT).
Trial: 33225952
Drug: High-dose thromboprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thromboprophylaxis (≥ 175 IU/kg of body weight tinzaparin or ≥ 200 IU/kg of body weight dalteparin)
Trial: 33225952
Drug: Medium-dose thromboprophylaxis
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose thromboprophylaxis (> 4500 IU but < 175 IU/kg of body weight tinzaparin or > 5000 IU but < 200 IU/kg of body weight dalteparin)
Trial: 33225952
Drug: Low-dose thromboprophylaxis
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose thromboprophylaxis (2500-4500 IU tinzaparin or 2500-5000 IU dalteparin)
Trial: 34875111
Drug: High-dose thromboprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thromboprophylaxis
Trial: 33225952
Drug: Medium-dose thromboprophylaxis
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose thromboprophylaxis
Trial: 33225952
Drug: Low-dose thromboprophylaxis
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose thromboprophylaxis
Trial: 33226334
Drug: Opioid use
RxNorm normalized name: Modia Opioid Use Disorder Support Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid use (measured in lowest recommended dosage units)
Trial: 33227125
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg/d
Trial: 33227125
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg/d (prior RTX treatment)
Trial: 33227125
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg/d (prior RTX-CIT treatment)
Trial: 33227125
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg/d (extranodal subtype)
Trial: 33227125
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg/d (nodal subtype)
Trial: 33227125
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg/d (splenic subtype)
Trial: 33227283
Drug: Biologics (n=642)
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics (n=642)
Trial: 33227283
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (n=227)
Trial: 33227350
Drug: Adequate first-line
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adequate first-line antibiotic treatment of proven bacterial infections
Trial: 33229362
Drug: Rilonacept 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept 320 mg SC load/160 mg SC weekly maintenance
Trial: 34465599
Drug: LY3300054 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3300054 monotherapy
Trial: 33229508
Drug: Expanded CD4
RxNorm normalized name: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine
DrugBank: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine (DB19219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expanded CD4 T cells cultured with high dose of interleukin-2 for up to 5 weeks
Trial: 33230035
Drug: Compensation training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compensation training and substitution therapies
Trial: 33230103
Drug: CD19-specific chimeric
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-specific chimeric antigen receptor T cell (CD19 CAR T) therapy
Trial: 33230210
Drug: peposertib 100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peposertib 100-200 mg once daily or 150-400 mg twice daily (BID) in 21-day cycles
Trial: 33230210
Drug: peposertib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peposertib 400 mg BID (RP2D)
Trial: 33230962
Drug: Ketosis (βHB:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketosis (βHB: 1.24±0.82 mmol/L in fasting)
Trial: 33231487
Drug: ACE-I/ARB therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-I/ARB therapy